STOCK TITAN

Athersys, Inc. - ATHX STOCK NEWS

Welcome to our dedicated page for Athersys news (Ticker: ATHX), a resource for investors and traders seeking the latest updates and insights on Athersys stock.

Athersys, Inc. (ATHX) is a clinical-stage biopharmaceutical company pioneering regenerative medicine therapies, with its lead investigational product MultiStem® targeting conditions like ischemic stroke and acute respiratory distress syndrome (ARDS). This page provides essential updates for stakeholders tracking the company’s scientific and corporate developments.

Access timely updates on clinical trial progress, regulatory milestones, strategic partnerships, and financial announcements. Our curated news collection helps investors and industry professionals stay informed about Athersys’ advancements in stem cell therapy and inflammatory disease treatments.

Key content includes updates on MultiStem® clinical studies, FDA communications, research collaborations, and pipeline expansion efforts. All information is sourced from verified channels to ensure accuracy and relevance.

Bookmark this page for streamlined access to Athersys’ latest developments. Check back regularly for objective reporting on innovations that could shape the future of regenerative medicine and impact long-term growth potential.

Rhea-AI Summary
Athersys, Inc. (OTC: ATHX) Announces Financial Results and Business Update, Including Interim Analysis of Phase 3 MASTERS-2 Clinical Trial for MultiStem Cell Therapy. The company also secured funding through warrant exercise and a Memorandum of Understanding with Healios for global rights to develop and commercialize MultiStem for the treatment of Acute Respiratory Distress Syndrome (ARDS). Athersys appointed Ms. Jane Wasman as Chair of the Board of Directors. Financially, the third quarter of 2023 showed a decrease in revenue, research and development expenses, and general and administrative expenses compared to the same period in 2022, resulting in a net loss of $(3.8) million. Cash and cash equivalents were $1.0 million as of September 30, 2023, compared with $9.0 million as of December 31, 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.79%
Tags
-
Rhea-AI Summary
Athersys announces warrant exercise inducement offer to raise $3.9 million and receives $1.5 million payment from HEALIOS K.K.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Athersys announces inconclusive results from Phase 3 trial for stroke treatment and enters into MOU with Healios for respiratory distress syndrome treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60%
Tags
Rhea-AI Summary
Athersys signs licensing agreement with Ardent Animal Health for non-human mammal applications of MAPC technology in the US. Athersys will receive initial fee, milestone payments, and royalties on commercial sales. Ardent also granted rights of first refusal for Athersys' cryogenic storage system. Positive partnership for Athersys in expanding its regenerative medicine applications in animal health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Athersys, Inc. announces changes to its Board of Directors. Jane Wasman appointed as Board Chair. Her expertise in strategic, operational, and corporate governance matters will be valuable. She is also chair of the board of directors of Sellas Life Sciences and a member of the board of directors of Rigel Pharmaceuticals. Positive for shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Athersys announces grant funding for study on potential use of MultiStem cellular therapy during machine perfusion prior to kidney transplantation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
Rhea-AI Summary
Athersys, Inc. announces the pricing of its public offering of common stock and warrants. The offering is expected to raise approximately $3.5 million for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.51%
Tags
-
Rhea-AI Summary
Athersys, Inc. (Nasdaq: ATHX) announced financial results for Q2 2023, with $48.8K in revenue compared to $2.3M in Q2 2022. Research and development expenses decreased to $10.6M from $20.8M, and general and administrative expenses decreased to $2.3M from $5.2M. Net loss for Q2 2023 was $(12.9)M, compared to $(23.6)M in Q2 2022. Cash and cash equivalents were $1.8M as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
management
Rhea-AI Summary
Athersys, Inc. (NASDAQ: ATHX) will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. The call will provide an overview of the company's recent clinical and operational progress, including the timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
conferences
Athersys, Inc.

OTC:ATHX

ATHX Rankings

ATHX Stock Data

833.20k
61.15M
0.77%
4.42%
3.72%
Biotechnology
Healthcare
Link
United States
Cleveland